Overview
Passage Bio Q3 net loss narrows to $7.7 mln from $19.3 mln yr/yr
Cash position decreased to $52.8 mln, funding operations into Q1 2027
Outlook
Passage Bio's cash runway extends into 1Q 2027
Result Drivers
R&D expenses were $4.3 million for the quarter ended September 30, 2025, as compared to $8.7 million for the quarter ended September 30, 2024.
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$7.75 mln
Q3 Income From Operations
-$8.66 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Passage Bio Inc is $53.50, about 88.3% above its November 7 closing price of $6.29
Press Release: ID:nGNX7VcgLp
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
